---
title: "Varegacestat (AL102) in Desmoid tumors: AL102-504"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: AL102-504. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 11 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence/al102-504"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: AL102-504

<a id="heading-3.1.7"></a>

## 3.1.7 AL102-504

<a id="heading-3.1.7.1"></a>

### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

#### Absorption, metabolism, excretion, and mass balance of carbon-14-labeled varegacestat

> “A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]Varegacestat Following a Single Oral Dose in Healthy Adult Male Participants”
> “This clinical study is designed to study the mass balance of a single dose of varegacestat in healthy male participants.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.2"></a>

### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

#### Registry status, dates, and site

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “AL102-504” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-02-25” |
| Primary completion (actual) | “2025-03-11” |
| Study completion (actual) | “2025-03-26” |
| Last update posted | “2025-09-26” |
| Site | “Frontage Laboratories, Inc.”; “Secaucus” |

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.3"></a>

### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

#### Single-center, open-label, single-dose radiolabel study

> “This is a single-center, open-label, Phase 1, mass balance study of varegacestat administered as a single oral dose (containing ~100 µCi) [14C]varegacestat in 6 healthy male participants.”
> “Whole blood, plasma, urine, feces, and vomitus (if any, up to 24 hours post-dose) will be collected over at least 168 hours post-dose.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="topic-3.1.7.3-2"></a>

#### Registry design fields

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.4"></a>

### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

#### Healthy men aged 18 to 55 years

> “Be a male participant between 18 and 55 years of age, inclusive, at Screening.”
> “Medically healthy based on the absence of clinically significant abnormal vital sign measurements, clinical laboratory test results (especially tests for renal and hepatic function), resting 12-lead Electrocardiogram (ECG) evaluation, and physical examination, as determined by the Investigator at Screening and the Check-In visit.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="topic-3.1.7.4-2"></a>

#### Exclusion of recent radiation exposure

> “Have participated in a radiolabeled drug study or have been otherwise exposed to significant diagnostic (excluding dental X-rays), therapeutic, or occupational radiation, where exposure is made known to the Investigator, within one year prior to admission to the clinic for this study.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.5"></a>

### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

#### Single dose of carbon-14-labeled varegacestat as two oral capsules after an overnight fast

> “Following completion of Screening and Day -1 assessments and an overnight fast of at least 10 hours, eligible participants will be administered a single dose (containing ~100 µCi) [14C]varegacestat as 2 oral capsules followed by approximately 240 mL room temperature filtered water on the morning of Day 1.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.6"></a>

### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

#### 3.1.7.6.1 Rationale for Using Mass Balance Recovery as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

##### Primary endpoint: mass balance

> “The mass balance of varegacestat following administration of a single oral dose (containing ~100 µCi) [14C]varegacestat in healthy adult male participants.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="topic-3.1.7.6.1-2"></a>

##### Secondary endpoints: total radioactivity, pharmacokinetics, metabolite profile, and safety

> “The total radioactivity in plasma, whole blood, urine, and feces following administration of a single oral dose (containing ~100 µCi) [14C]varegacestat in healthy adult male participants.”
> “Maximum observed concentration (Cmax) of varegacesatat and AL102-MTB (Varegacestat metabolite) in plasma.”
> “Percentage of each metabolite in urine and feces relative to the administered dose or percentage of metabolites in plasma relative to total drug related exposure AUC.”
> “The safety and tolerability of a single oral dose (containing ~100 µCi) [14C]varegacestat in healthy adult male participants by incidences of treatment-emergent adverse events.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.7"></a>

### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

#### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

##### Actual enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (actual) | “6” |

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="heading-3.1.7.7.2"></a>

#### 3.1.7.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.7.8"></a>

### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

#### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

#### 3.1.7.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.7.8.3"></a>

#### 3.1.7.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.7.8.4"></a>

#### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

#### 3.1.7.8.5 Safety Results

No evidence found.

<a id="heading-3.1.7.9"></a>

### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

#### Summary

- AL102-504 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-03-11, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the routes of elimination and the metabolite profile of varegacestat are unknown from public sources.
- The study enrolled 6 healthy men aged 18 to 55 years and gave a single dose of approximately 100 µCi of [14C]varegacestat, so it provides no data in women, in patients with desmoid tumors, or at steady state.

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
